Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT04144725
Active, not recruiting Observational

Ruling Out Coronary Artery Disease and Myocardial Injury by Biomarkers

NCT04144725 · tracked via the Priya Life Science Norway tracker
Sponsor
University Hospital, Akershus
Phase
Observational
Started
2019-10-23
Last updated
2026-06-09

Condition(s) studied

Coronary Artery Disease

Study summary

A considerable proportion of patients with clinically suspected coronary artery disease (CAD) do not have angiographic signs of luminal narrowing caused by coronary atherosclerosis. In patients with suspected CAD, we will assess the ability of cardiovascular biomarkers to identify patients with (a) angiographically normal epicardial coronary vessels (b) absence of significant epicardial coronary stenosis, as assessed by coronary computed tomography angiography (CCTA). Patients will be stratified according to the presence or absence of dynamic changes of high sensitivity cardiac troponin T levels above the 99th percentile.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Consenting patient over the age of 18 referred to CCTA for suspected coronary artery disease Exclusion Criteria: * Inability to provide informed consent. * Short life expectancy (\<12 months) due to non-cardiovascular disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Akershus University Hospital Lørenskog Norway

More University Hospital, Akershus trials in Norway

Mechanisms of Persistent Fatigue Recruiting
Akershus Cardiac Examination (ACE) 5 Study Recruiting
Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease Active, not recruiting
Continuous Vital Sign Monitoring in a Surgical Ward Recruiting
Tailoring Treatment in Colorectal Cancer Recruiting

Other trials for the same condition

Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study Active, not recruiting
Coronary Artery Plaque Burden in Stable Angina and Non-obstructive Coronary Artery Disease Active, not recruiting
Electronic Cardiac Rehabilitation (eCardiacRehab) Feasibility Study Active, not recruiting
Digital Long-term Follow-up of Patients With Coronary Artery Disease Recruiting
Patient-reported Outcomes After Percutaneous Coronary Intervention Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04144725 on ClinicalTrials.gov ↗ ← All trials in Norway